GDAP1 Gene CMT2K Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines

تحليل جين GDAP1 لمرض CMT2K عبر التسلسل الجيني (NGS) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي

الملخص التنفيذي:

يقدم هذا التحليل الجيني المتقدم باستخدام تقنية التسلسل من الجيل التالي (NGS) تشخيصًا دقيقًا لطفرة جين GDAP1 المرتبطة بمرض شاركو ماري توث من النوع 2K، وفقًا لأعلى معايير هيئة الصحة بدبي والقوانين الاتحادية.

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Overview

The GDAP1 Gene CMT2K Genetic Test uses next-generation sequencing to detect pathogenic variants in the GDAP1 gene, confirming a diagnosis of Charcot-Marie-Tooth disease type 2K (CMT2K) or assessing carrier status. يوفر هذا الاختبار أعلى دقة تشخيصية لمرضى الاعتلال العصبي الوراثي.

Pre-Test Requirements: A mandatory genetic counseling session to draw a pedigree chart of family members affected with GDAP1 gene CMT2K is required before sample collection. This ensures accurate interpretation and patient understanding.

Feature	Our Test (NGS)	Closest Alternative (Sanger Sequencing)
Methodology	Next-Generation Sequencing	Sanger Sequencing (single gene)
Turnaround Time	3–4 Weeks	6–8 Weeks
Analytical Sensitivity	>99.9% for SNVs, indels	Limited; may miss deep intronic variants
Sample Type	Whole Blood, Extracted DNA, Dried Blood Spot (FTA Card)	Whole Blood

Physician Insight & Safety Protocol

Dr. Prabhakar Reddy, DHA 61713011, Consultant Neurologist:

A positive result should be correlated with clinical symptoms and family history; genetic counseling is essential before and after testing. As a DHA-licensed neurologist, I emphasize that this test is one piece of your diagnostic puzzle. Please do not make any treatment decisions based solely on this result.

Medication Warning:

Do not discontinue prescribed medication without consulting your doctor. This test does not replace clinical judgment.

Exclusion Criteria & Emergency Red Flags

Exclusion: Individuals who have received a blood transfusion within the past 2 weeks; alternative sample (buccal swab) may be considered. Minors (<18 years) require informed parental consent in accordance with UAE CDS Law 2026.
ER Red Flags: If you experience sudden severe neurological symptoms like acute limb weakness, breathing difficulty, or loss of consciousness, seek emergency medical attention immediately—do not wait for test results.

Patient FAQ & Clinical Guidance

Q: What is the GDAP1 Gene CMT2K NGS test, and why is it done?

A: The GDAP1 Gene CMT2K NGS test detects mutations in the GDAP1 gene causing Charcot-Marie-Tooth disease type 2K, an inherited neuropathy. This test is used to confirm a clinical diagnosis, guide prognosis, and inform family planning decisions. It is recommended for individuals with suspected CMT2K based on clinical findings and nerve conduction studies.

Q: How accurate is this test, and how long do results take?

A: The test achieves over 99.9% analytical sensitivity for point mutations and small indels using next-generation sequencing technology, with results delivered in 3–4 weeks. The high coverage ensures reliable detection, and our ISO-certified process minimizes false negatives. Pre- counseling ensures you understand the implications.

س: هل يحتاج هذا الاختبار إلى صيام أو تحضير معين؟

ج: لا يحتاج هذا الاختبار إلى صيام، ويمكن إجراؤه باستخدام عينة دم بسيطة أو بطاقة FTA، مع جلسة استشارة وراثية مسبقة. يُرجى التواصل مع فريقنا عبر واتساب لتنسيق الجلسة قبل سحب العينة.

In compliance with Federal Decree-Law No. 41 of 2024 (Art. 87), UAE PDPL (Federal Decree-Law No. 45 of 2021), and ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139). Facility License: 9834453.

دعم ثنائي اللغة متاح